In the traditional model of real-world evidence (RWE) generation, sponsors relied almost automatically on contract research organizations (CROs) to manage observational studies end to end. That model made sense when data were fragmented, technology limited, and sponsors lacked internal capacity. Today, the landscape is very different. Data networks are richer, analytical platforms are significantly more advanced, and many sponsors have grown their own RWE teams. Naturally, the question emerges: Do you still need a CRO to run your RWE study?
Over the last decade, several data vendors and technology platforms have evolved beyond simple data provision. They now support feasibility assessments, study simulation, protocol drafting, cohort building, analytics, and even regulatory-grade documentation. Platforms such as Palantir, Medidata, BC Platforms, and TriNetX (including disease-specific networks) can work directly with sponsors, giving them real-time visibility into cohort sizes, data quality, and study progress. In parallel, governance processes have become more standardised, and many studies using secondary data no longer require traditional site initiation or field-based operations.
This shift has real implications. Data vendors, as custodians of their datasets, typically understand data structure, limitations, and quality nuances more deeply than a global CRO interpreting the same dataset second-hand. Removing unnecessary layers of communication and oversight can reduce costs and accelerate timelines. As a result, sponsors increasingly handle many activities in-house, supported by targeted external expertise. A specialised consultant can help with data-source assessment, protocol development, ethics submissions or governance pathways, and overall study steering, without the overhead of outsourcing to a full global CRO.
Where Global CROs Still Add Value
Global CROs still matter, but their value is now conditional rather than universal. They remain useful for:
- Hybrid or prospective designs involving physician engagement, site initiations, patient-reported outcomes, or chart abstraction.
- Sponsors lacking internal operational expertise, where full project management infrastructure is still required.
- Studies approaching the complexity of clinical trials, where GCP-aligned systems, PV infrastructure, and quality frameworks are necessary.
Their strength lies in scale, regulatory familiarity, and operational discipline across markets. But for pure secondary-data studies, these strengths are not always needed, and can even slow things down.
Why Small, Specialized CROs and Consultants Remain High-Value
The move away from large CROs does not mean abandoning CRO expertise altogether. Many smaller, niche CROs (particularly those deeply familiar with local data environments or therapeutic domains) offer precisely what large CROs often lack: contextual expertise.
- Small local CROs often have hands-on knowledge of regional data governance, ethics processes, and registry-specific nuances (for example, understanding the structure of disease registries in the Nordics or navigating local ethics submission paths).
- Therapeutic-area-focused CROs, such as those specialized in vaccine RWD, can provide critical methodological expertise (e.g., understanding seasonality, immunization registries, dosing intervals, cold-chain documentation, or safety-signal expectations). In domains like vaccines, this depth of experience can be more valuable than generalist operational scale.
These smaller partners are often more cost-effective, more agile, and more directly involved in the scientific content, and they integrate well with data-platform models.
Data Vendors and Tech Platforms: What They Must Build
As sponsors turn to platforms and data vendors for execution, these organizations must continue to strengthen their operational layers. It is no longer enough to provide data access. They need:
- Dedicated RWE operations teams who understand regulatory expectations and study governance.
- Working processes for protocol development, ethics submission coordination, and communication with oversight bodies.
- Validated and audit-ready pipelines for feasibility, extraction, and analytics.
- Clear risk-management, quality, and transparency frameworks.
- Seamless interoperability with sponsor systems and external analytical environments.
When these components are in place, data platforms do more than replace CROs, they redefine how RWE is executed.
Choosing the Right Model: A Sponsor Framework
Selecting the right partner model requires an honest assessment of study complexity and internal capability:
- Secondary-data studies with limited regulatory burden often benefit from a lean model: tech platform + strategic consulting/local CRO + targeted operational support.
- Studies with multi-layered governance or prospective components may still require CRO involvement.
- Sponsors with strong internal RWE teams can take on far more than they could a decade ago, provided partners offer operational maturity and transparent delivery models.
Hybrid models are becoming the norm: sponsors retain strategic ownership, while external experts fill specific operational or methodological gaps.
Looking Ahead
The RWE setting is shifting toward agility and precision rather than size and legacy infrastructure. Large global CROs are no longer the default option for non-interventional studies, and sponsors now have alternatives that can deliver higher quality, faster timelines, and improved cost efficiency. At the same time, specialized small CROs and consultants continue to offer irreplaceable domain expertise and pragmatism.
As platforms mature and data ecosystems evolve, the most successful RWE strategies will be those that challenge old outsourcing habits and select partners based on fit-for-purpose value, not on historical convention.
